ALK-Abelló Valuation
Is ALK B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALK B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALK B (DKK173.4) is trading below our estimate of fair value (DKK189.79)
Significantly Below Fair Value: ALK B is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALK B?
Other financial metrics that can be useful for relative valuation.
What is ALK B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 37.96b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.3x |
Enterprise Value/EBITDA | 34.5x |
PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does ALK B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 21.3x | ||
HLUN B H. Lundbeck | 18.9x | 10.2% | DKK 46.6b |
NOVO B Novo Nordisk | 39.6x | 14.4% | DKK 3.6t |
GMAB Genmab | 17.8x | 19.4% | DKK 98.7b |
RICHTER Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt | 8.8x | 11.9% | Ft2.0t |
ALK B ALK-Abelló | 55.6x | 27.5% | DKK 38.0b |
Price-To-Earnings vs Peers: ALK B is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the peer average (21.3x).
Price to Earnings Ratio vs Industry
How does ALK B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ALK B is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the European Pharmaceuticals industry average (23.2x).
Price to Earnings Ratio vs Fair Ratio
What is ALK B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 55.6x |
Fair PE Ratio | 34.7x |
Price-To-Earnings vs Fair Ratio: ALK B is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | DKK 173.40 | DKK 177.00 +2.1% | 9.3% | DKK 200.00 | DKK 153.00 | n/a | 5 |
Oct ’25 | DKK 171.10 | DKK 177.00 +3.4% | 9.3% | DKK 200.00 | DKK 153.00 | n/a | 5 |
Sep ’25 | DKK 179.00 | DKK 168.60 -5.8% | 15.3% | DKK 200.00 | DKK 128.00 | n/a | 5 |
Aug ’25 | DKK 156.50 | DKK 155.40 -0.7% | 11.5% | DKK 180.00 | DKK 128.00 | n/a | 5 |
Jul ’25 | DKK 151.10 | DKK 155.40 +2.8% | 11.5% | DKK 180.00 | DKK 128.00 | n/a | 5 |
Jun ’25 | DKK 152.60 | DKK 155.00 +1.6% | 11.4% | DKK 175.00 | DKK 126.00 | n/a | 5 |
May ’25 | DKK 131.20 | DKK 132.75 +1.2% | 7.6% | DKK 145.00 | DKK 120.00 | n/a | 4 |
Apr ’25 | DKK 124.10 | DKK 125.00 +0.7% | 15.0% | DKK 140.00 | DKK 94.00 | n/a | 4 |
Mar ’25 | DKK 130.40 | DKK 120.75 -7.4% | 16.5% | DKK 140.00 | DKK 94.00 | n/a | 4 |
Feb ’25 | DKK 110.70 | DKK 112.00 +1.2% | 10.6% | DKK 125.00 | DKK 94.00 | n/a | 4 |
Jan ’25 | DKK 101.20 | DKK 110.75 +9.4% | 9.6% | DKK 120.00 | DKK 94.00 | n/a | 4 |
Dec ’24 | DKK 91.75 | DKK 110.75 +20.7% | 9.6% | DKK 120.00 | DKK 94.00 | n/a | 4 |
Nov ’24 | DKK 76.45 | DKK 117.80 +54.1% | 21.3% | DKK 160.00 | DKK 89.00 | n/a | 5 |
Oct ’24 | DKK 79.45 | DKK 112.80 +42.0% | 25.2% | DKK 160.00 | DKK 85.00 | DKK 171.10 | 5 |
Sep ’24 | DKK 83.10 | DKK 116.40 +40.1% | 22.5% | DKK 160.00 | DKK 85.00 | DKK 179.00 | 5 |
Aug ’24 | DKK 74.15 | DKK 128.20 +72.9% | 23.6% | DKK 169.00 | DKK 95.00 | DKK 156.50 | 5 |
Jul ’24 | DKK 74.45 | DKK 128.20 +72.2% | 23.6% | DKK 169.00 | DKK 95.00 | DKK 151.10 | 5 |
Jun ’24 | DKK 82.15 | DKK 124.20 +51.2% | 27.0% | DKK 169.00 | DKK 90.00 | DKK 152.60 | 5 |
May ’24 | DKK 86.50 | DKK 129.20 +49.4% | 22.6% | DKK 169.00 | DKK 100.00 | DKK 131.20 | 5 |
Apr ’24 | DKK 106.10 | DKK 141.20 +33.1% | 15.6% | DKK 169.00 | DKK 107.00 | DKK 124.10 | 5 |
Mar ’24 | DKK 103.70 | DKK 142.20 +37.1% | 16.4% | DKK 174.00 | DKK 107.00 | DKK 130.40 | 5 |
Feb ’24 | DKK 102.60 | DKK 139.80 +36.3% | 18.0% | DKK 174.00 | DKK 105.00 | DKK 110.70 | 5 |
Jan ’24 | DKK 96.05 | DKK 142.20 +48.0% | 20.2% | DKK 186.00 | DKK 105.00 | DKK 101.20 | 5 |
Dec ’23 | DKK 102.90 | DKK 142.20 +38.2% | 20.2% | DKK 186.00 | DKK 105.00 | DKK 91.75 | 5 |
Nov ’23 | DKK 116.40 | DKK 161.50 +38.7% | 14.6% | DKK 195.00 | DKK 132.50 | DKK 76.45 | 5 |
Oct ’23 | DKK 120.80 | DKK 170.50 +41.1% | 13.0% | DKK 195.00 | DKK 132.50 | DKK 79.45 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.